TW202334224A - SIRPγ抗體及其用途 - Google Patents

SIRPγ抗體及其用途 Download PDF

Info

Publication number
TW202334224A
TW202334224A TW111142996A TW111142996A TW202334224A TW 202334224 A TW202334224 A TW 202334224A TW 111142996 A TW111142996 A TW 111142996A TW 111142996 A TW111142996 A TW 111142996A TW 202334224 A TW202334224 A TW 202334224A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
antibody
sequence
Prior art date
Application number
TW111142996A
Other languages
English (en)
Chinese (zh)
Inventor
珊迪普 潘尼克
亞當 大衛 羅森塔爾
伊琳 靈休 羅斯
國楊 蔡
Original Assignee
美商電子療法股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商電子療法股份有限公司 filed Critical 美商電子療法股份有限公司
Publication of TW202334224A publication Critical patent/TW202334224A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW111142996A 2021-11-10 2022-11-10 SIRPγ抗體及其用途 TW202334224A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163277966P 2021-11-10 2021-11-10
US63/277,966 2021-11-10

Publications (1)

Publication Number Publication Date
TW202334224A true TW202334224A (zh) 2023-09-01

Family

ID=84488592

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142996A TW202334224A (zh) 2021-11-10 2022-11-10 SIRPγ抗體及其用途

Country Status (11)

Country Link
US (1) US20240400677A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429768A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024543385A (cg-RX-API-DMAC7.html)
KR (1) KR20240099454A (cg-RX-API-DMAC7.html)
CN (1) CN118591556A (cg-RX-API-DMAC7.html)
AU (1) AU2022386652A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237787A1 (cg-RX-API-DMAC7.html)
IL (1) IL312776A (cg-RX-API-DMAC7.html)
MX (1) MX2024005740A (cg-RX-API-DMAC7.html)
TW (1) TW202334224A (cg-RX-API-DMAC7.html)
WO (1) WO2023086906A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
TW202547858A (zh) * 2024-04-22 2025-12-16 美商電子療法股份有限公司 用於治療愛潑斯坦—巴爾病毒感染之SIRPα及β抗體

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
MX2021015937A (es) * 2019-06-24 2022-02-03 Amgen Inc Inhibicion de sirp-gamma para el tratamiento del cancer.

Also Published As

Publication number Publication date
WO2023086906A3 (en) 2023-06-22
CN118591556A (zh) 2024-09-03
AU2022386652A1 (en) 2024-06-06
IL312776A (en) 2024-07-01
KR20240099454A (ko) 2024-06-28
WO2023086906A2 (en) 2023-05-19
MX2024005740A (es) 2024-08-06
US20240400677A1 (en) 2024-12-05
JP2024543385A (ja) 2024-11-21
CA3237787A1 (en) 2023-05-19
EP4429768A2 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
KR102422411B1 (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
CN109475603B (zh) 抗pd-l1抗体
KR102100467B1 (ko) Cd33 항체 및 암을 치료하기 위한 이의 용도
CN114007699A (zh) 拮抗剂抗cd7抗体
JP7170331B2 (ja) 固形及び血液癌の治療のための併用療法
CN113164598A (zh) 双特异性抗cd28 x抗cd22抗体以及其用途
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
CN104119438A (zh) 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
US20240400677A1 (en) Sirp gamma antibodies and uses thereof
KR20220129030A (ko) 항-Gal3 항체 및 사용 방법
KR20140127875A (ko) 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도
KR20140015138A (ko) 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Fc 영역-함유 폴리펩티드, 그것의 사용 방법
JP2023010810A (ja) 抗SIRPg抗体の新規の使用
CN115768795A (zh) SIRPα及SIRPβ1抗体及其用途
JP7843824B2 (ja) 抗体および使用方法
JP2015515456A (ja) 抗cd19抗体による多発性硬化症の治療
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
CN115210261A (zh) 抗半乳糖凝集素-9抗体及其用途
JP7430137B2 (ja) 抗体および使用方法
CA3207703A1 (en) Anti-s100a4 humanized antibodies, uses and methods
JP2022550364A (ja) 新規抗pd-l1/抗lag-3二重特異性抗体およびその使用
KR20230154981A (ko) 항-인간 cxcr5 항체 및 이의 용도
TW202506735A (zh) 抗fgfr2b抗體、其製備方法及其用途
KR20260036407A (ko) 항-tigit 항체 및 이의 용도
KR20220053000A (ko) Cr2 결합 단백질 및 의료 요법에서의 그의 용도